{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-143665","form_type":"8-K","ticker":"PSTV","cik":"0001095981","company_name":"PLUS THERAPEUTICS, INC.","filed_at":"2025-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.504543+00:00","generated_at":"2026-05-19T00:49:32.896280+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Plus Therapeutics enters $50M common stock purchase agreement with Lincoln Park Capital","bullets":["Plus Therapeutics signed a purchase agreement with Lincoln Park Capital for up to $50 million of common stock over 36 months.","Lincoln Park commits to buy up to 300,000 shares per regular purchase (up to 500,000 at higher prices) at 97% of market price.","The company will pay a $500,000 initial commitment fee in cash or stock, plus $500,000 after reaching $25 million in sales.","Proceeds will fund working capital and a $17.3 million make-whole repayment to March 2025 warrant holders.","Issuance beyond 10,194,593 shares requires shareholder approval unless average sale price exceeds $0.3576."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-143665","json":"https://secwatch.observer/filing/0001193125-25-143665.json","markdown":"https://secwatch.observer/filing/0001193125-25-143665.md","text":"https://secwatch.observer/filing/0001193125-25-143665.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1095981/000119312525143665/0001193125-25-143665-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1095981/000119312525143665/d925162d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-19T00:49:32.896280+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}